Previous 10 | Next 10 |
Even the best stocks can fall on hard times. That's certainly been the case with plenty of biotech stocks over the past 12 months. However, some that have floundered could still be huge winners over the long term. We asked three Motley Fool contributors to pick beaten-down stocks they t...
Image source: The Motley Fool. Novocure (NASDAQ: NVCR) Q1 2022 Earnings Call Apr 28, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Novocure (NVCR) Q1 2022 Earnings Call Transcript
NovoCure Limited (NVCR) Q1 2022 Earnings Conference Call April 28, 2022 8:00 AM ET Company Participants Ingrid Goldberg – Investor Relations Bill Doyle – Executive Chairman Ashley Cordova – Chief Financial Officer Pritesh Shah – Chief Commercial Officer Ely Benaim ...
NovoCure press release (NASDAQ:NVCR): Q1 GAAP EPS of -$0.04 beats by $0.15. Revenue of $137.55M (+2.1% Y/Y) beats by $3.26M. Gross margin for the quarter was 80%. As of March 31, 2022, there were 3,549 active patients on therapy. Active patients from North America, EMEA and Ja...
Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2022. Novocure is a globa...
NovoCure (NASDAQ:NVCR) is scheduled to announce Q1 earnings results on Thursday, April 28th, before market open. The consensus EPS Estimate is -$0.19 and the consensus Revenue Estimate is $134.29M (-0.3% Y/Y). Over the last 1 year, NVCR has beaten EPS estimates 25% of the time and has be...
Healthcare is arguably the most regulated industry in the stock market. Before a company is allowed to market a drug to the public, it has to pay for expensive clinical trials that prove a drug is both safe and effective. So getting an approval from the Food and Drug Administration (FDA) is...
Governor Sununu and Novocure leadership delivered keynote remarks, celebrating the construction of Novocure’s new flagship facility in Portsmouth, NH Today, Governor Chris Sununu (R-NH) joined Novocure for a ceremonial event commemorating the start of construction of ...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Small cap stocks had a rough ride during the first quarte...
Investing in biotechnology companies is both difficult and incredibly exciting. Watching as a company goes through the regulatory approval process, from a fledgling early-stage clinical trial biotech to an industry juggernaut, can be exhilarating. While positive outcomes aren't guarante...
News, Short Squeeze, Breakout and More Instantly...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...
2024-06-13 14:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 10:45:03 ET Wells Fargo analyst issues NEUTRAL recommendation for NVCR on June 4, 2024 09:01AM ET. The previous analyst recommendation was Neutral. NVCR was trading at $24.055 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...